Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This study will be a prospective observational study of "real world" BDP nasal aerosol users
with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly
online surveys regarding rhinitis control, concomitant medical conditions, concomitant
(non-AR) medications, current AR therapy, and adverse events.
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries
Collaborators:
United BioSource Corporation United BioSource, LLC